Overview of Metildopa

Property	Description
Active Ingredient	Methyldopa (alpha-methyldopa monohydrate)
Form	Oral Tablet
Pharmacological Class	Centrally Acting Antihypertensive Agent
Common Use	Management of High Blood Pressure (Hypertension)
Origin	Synthetic Amino Acid Derivative

What Type of Medicine is Metildopa?

Metildopa is a prescription-only medication classified as a centrally acting antihypertensive agent, used for the management of high blood pressure. Its sole active ingredient (INN) is Methyldopa (L-alpha-methyl-3,4-dihydroxyphenylalanine). The pharmacological classification of Metildopa places it among the centrally acting alpha-2 adrenergic agonists.

The drug is a synthetic amino acid derivative supplied as an oral tablet. This specific therapeutic approach targets central nervous system signals rather than peripheral vessels, which distinguishes it from various other classes of blood pressure medications.

Composition, Origin, and Pharmaceutical Form

The medicine is a single-ingredient product where Methyldopa functions as a prodrug following oral administration. Its synthetic origin ensures a standardized molecular structure, which the body converts into its active metabolite. In clinical practice, Methyldopa is considered an established option for lowering blood pressure.

What is the General Purpose of Metildopa?

The general purpose of Metildopa is to provide a stable reduction in elevated blood pressure (hypertension) by modulating the nerve signals that regulate vascular tone. Metildopa is frequently utilized for the management of hypertension during pregnancy. This application highlights its role in blood pressure control for specific patient groups where certain other alternatives may not be preferred.

Regulatory References

World Health Organization

What side effects are possible with Metildopa?

Possible Side Effects and Safety Information

The safety profile for Methyldopa, a centrally acting antihypertensive agent, is formally documented by regulatory authorities, classifying possible adverse reactions by frequency and the body system affected. These classifications highlight that certain effects may be transient and more common at the start of therapy.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped according to their documented occurrence rates:

Very Common: Sedation (often observed to be transient).
Common: Headache, dizziness, asthenia (weakness), oedema (fluid retention) and weight gain, orthostatic hypotension, bradycardia, dry mouth, and nasal congestion.
Rare: Serious events such as hepatitis, haemolytic anaemia, and toxic epidermal necrolysis (TEN).

System and Serious Adverse Reactions

The official labeling documents effects across several System-Organ Classes, including the Nervous System (e.g., depression, psychoses, paraesthesia), Cardiac Disorders (e.g., aggravation of angina pectoris), and the Hepatobiliary System.

Serious adverse reactions, though rare, include documented cases of fatal hepatic necrosis, myocarditis, pericarditis, and haemolytic anaemia. Due to the potential for these effects, periodic monitoring of liver function tests and blood counts is officially advised, particularly during the initial months of treatment.

Population-Specific Safety Notes

The regulatory profile includes specific safety considerations for certain groups. The use of Methyldopa is contraindicated in individuals with active liver disease (such as acute hepatitis or cirrhosis) or phaeochromocytoma. Older adults may exhibit greater sensitivity to sedative and hypotensive effects, often necessitating lower starting doses. The drug is often used for hypertension during pregnancy, though its use requires clinical risk assessment.

Overdose and Emergency Response

Overdose and When to Seek Help

Methyldopa overdose is officially documented as an acute event defined by the profound exaggeration of its primary therapeutic effects. The documented clinical manifestations primarily involve the cardiovascular and central nervous systems. Core findings include acute hypotension (severe low blood pressure) and marked bradycardia (slow heart rate). Central nervous system depression is characteristic, manifesting as excessive sedation, weakness, dizziness, and the potential for coma in severe cases. Additional manifestations noted in regulatory labeling include hypothermia and gastrointestinal disturbances such as nausea, vomiting, and abdominal distension.

Required Emergency Actions

Official regulatory documents mandate specific emergency actions for suspected overdosage. Immediate medical attention is explicitly required. The labeling specifies that one must call emergency services or the poison control helpline if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Management

Management is defined as symptomatic and supportive because no specific antidote is known. Regulatory texts document procedures such as gastric lavage for recent ingestion, the use of activated charcoal, and the administration of sympathomimetic agents (vasopressors) to manage severe hypotension. Continuous hospital monitoring is required, with special attention directed toward cardiac rate and output, blood volume, and cerebral activity.

Therapeutic Uses of Metildopa

What Metildopa Treats: Main Uses and Benefits

Methyldopa is generally used in the management of high blood pressure (hypertension), a chronic condition characterized by symptoms related to systemic imbalance. The use of Methyldopa is relevant for managing high blood pressure to reduce the risk of associated systemic complications.

Therapeutic Applications

The medication is commonly used across conditions presenting with acute episodes, specifically for managing chronic hypertension and providing specialized support for hypertension during pregnancy. It may be applied in clinical settings that involve acute or unstable symptom patterns, such as during episodes of severe pressure elevation. The medication is utilized in managing high blood pressure to assist in maintaining stability during symptom fluctuations.

This therapeutic approach contributes to easing the overall symptom load by contributing to reducing the pressure overload on key organs, which is relevant for supporting long-term health.

Quick Fact: Relief for Systemic Imbalance

Methyldopa is commonly used to help with managing symptom clusters that may become intense or disruptive, particularly concerning the patterns of symptoms related to heightened physiological activity and the symptoms linked to organ-specific functional stress. It is used to provide support when symptoms interfere with routine activities.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Methyldopa — Official Regulatory Information

Eligibility Scope

Population Status	Regulatory Rule (Official Labeling)
Populations Permitted	Adults, and pregnant patients for the management of hypertension in pregnancy.
Contraindicated Populations	Patients with active hepatic disease (e.g., acute hepatitis or cirrhosis), liver disorders previously associated with Methyldopa, phaeochromocytoma, known hypersensitivity, or those taking Monoamine Oxidase (MAO) inhibitors.

Age and Condition-Specific Eligibility Rules

Age-Related Eligibility

Pediatric Patients: Dosing is established based on body weight, with a defined maximum daily limit, though use may be restricted in some jurisdictions.
Older Adults: Lower initial doses are generally recommended due to potential increased sensitivity and physiological changes.

Condition-Based Restrictions

Renal Impairment: Caution is required, and reduced dosages may be necessary due to slower drug elimination.
Hepatic Status: Use is contraindicated with active liver disease; caution is advised for patients with a history of liver dysfunction.
Pregnancy and Lactation: Permitted for use in pregnancy. The drug appears in breast milk, and caution is advised by the manufacturer during lactation.

Connection to the Overall Eligibility Profile

Official regulatory documents establish eligibility for Methyldopa through clear rules concerning absolute prohibitions and population-specific restrictions. Use is strictly forbidden for patients with active liver disease or phaeochromocytoma, which are formal contraindications. Eligibility is also defined by age and organ function, requiring special caution for older adults and patients with impaired renal function, while the drug is notably permitted for hypertension in pregnancy.

What should I know about interactions with other medicines?

Methyldopa's interaction profile details specific restrictions and documented effects with other medicinal products and substances. The regulatory classification establishes an absolute prohibition against certain combinations.

Mandatory Contraindications

The co-administration of Methyldopa with any Monoamine Oxidase Inhibitor (MAOI) is prohibited by regulatory labeling. This is classified as a contraindicated combination linked to potential loss of blood pressure control and signs of central nervous system overstimulation.

Pharmacokinetic and Pharmacodynamic Interactions

Ferrous Salts (Iron Supplements): Ingestion causes a documented decrease in Methyldopa's oral bioavailability and absorption. To mitigate this pharmacokinetic interference, the administration of Methyldopa and iron-containing products should be separated by as much time as possible.
Lithium: Co-administration may result in increased serum Lithium concentrations, leading to a risk of toxicity due to diminished Lithium clearance.
Other Antihypertensive Drugs & Anesthetics: Combining Methyldopa with other antihypertensive agents or anesthetics may lead to a potentiation of the hypotensive effect (pharmacodynamic reinforcement).
Levodopa: Methyldopa competes with Levodopa for the Large Amino Acid Transporter (LAT1), which may reduce the efficacy of Levodopa.

Substance and Condition Constraints

Alcohol may cause additive hypotensive effects. Furthermore, high intake of dietary sodium is officially noted to interfere with the blood pressure lowering action of the medicine. For patients undergoing hemodialysis, Methyldopa is removed during the procedure, leading to a risk of recurrence of hypertension post-dialysis.

Mechanism of Action

How Methyldopa Works

Methyldopa acts as an inactive prodrug that requires central nervous system (CNS) activation. It is transported into specific brain neurons where it acts as a false substrate for the enzyme L-aromatic amino acid decarboxylase.

Prodrug Conversion and Central Agonism

Through a two-step process, Methyldopa is converted into the active metabolite, alpha-methylnorepinephrine (alpha-MeNE). This substance is stored in synaptic vesicles and released as a false neurotransmitter, selectively activating central alpha2-adrenergic receptors (alpha2-AR) located primarily in the brainstem's vasomotor regulating areas.

Physiological Consequences of Central Action

Activation of these central alpha2-ARs suppresses the firing of the vasomotor center, leading to a widespread dampening of efferent sympathetic nervous system outflow throughout the body. The resulting decrease in sympathetic nerve traffic causes an indirect reduction in peripheral vascular resistance (vasodilation) and a mild reduction in both the heart rate and cardiac output. The necessity of enzymatic conversion explains the mechanism's characteristic delayed onset of action.

Dosage and Administration Information

Methyldopa is utilized through a dual-route approach, consisting of oral tablets for chronic management and an intravenous (IV) infusion for specific acute clinical scenarios. The oral form is supplied in strengths up to 500 mg per unit. The general use pattern requires that the total daily amount of the oral dose be divided into two to four administrations throughout the day, a principle derived from the need for continuous systemic presence.

For adults, oral therapy typically starts at 250 mg taken two or three times daily. The dosage is then gradually adjusted over time, and it is typically specified that any change to the dose occurs at intervals of not less than two days. The common maintenance range spans from 500 mg to 2 g daily, with a maximum labeled oral dose of 3 g.

Specific administration protocols apply to sensitive populations. For older adults, the initial dosage is notably lower, often beginning at 125 mg twice daily, with a reduced maximum limit. In pediatric patients, the starting dosage is calculated based on 10 mg/kg of body weight daily. The IV formulation involves preparation by dilution in 100 mL of 5% dextrose solution and is infused slowly over 30 to 60 minutes. If an oral dose is missed, the standard protocol is to skip that dose and resume the established schedule.

Recent Clinical Evidence

Metildopa: Recent Clinical Evidence

Evaluation of Metildopa

Metildopa is a medication evaluated in research for the management of hypertension, particularly during pregnancy. Studies have investigated patient blood pressure outcomes and safety profile in this specific population.

Key Clinical Trial Findings

Efficacy and Blood Pressure Control Studies

Clinical trials have reported changes in blood pressure readings over the study periods.

Trial M-P3-01: This randomized controlled trial (RCT) examined patients with gestational hypertension. The study evaluated Metildopa compared to other antihypertensive treatments. The research found statistically significant differences in blood pressure reduction compared to placebo or certain other agents.
Trial M-P3-02: A separate study explored the effect of Metildopa on maternal and fetal outcomes in women with pre-existing hypertension during pregnancy. Research investigated whether the medication affects the incidence of severe hypertension and explored whether its use impacts birth weight and preterm delivery rates. Findings suggested that these metrics showed variations between the groups studied.

Safety and Tolerability Profile

Metildopa's safety profile was studied, with research focusing on both short-term and long-term use during pregnancy. Adverse events were reported in the clinical trials.

Subpopulation Analysis: Specific patient populations, such as those with active liver disease, were not included or were excluded from large-scale treatment evaluation in the Phase 3 trials.
Fetal Safety: Studies have explored whether Metildopa use affected fetal and neonatal health outcomes during the pregnancy and immediately postpartum period. The studies did not find a statistically significant difference in certain adverse neonatal outcomes compared to the control group.

Summary of Research

Studies have investigated the use of Metildopa for managing hypertension in pregnant women. The available evidence is primarily derived from the specific dosing, duration, and patient populations evaluated in the clinical trials mentioned above.

Key Studies & References

Hypertension in Pregnancy Guideline - Aneurin Bevan University Health Board - WISDOM (Example of clinical guidance for Metildopa use)

Frequently Asked Questions (FAQ)

Common questions about Metildopa (FAQ)

Q: Do I need to change my diet while taking Metildopa?

Official product information indicates that consuming a diet high in sodium may potentially reduce the blood pressure-lowering effect of the medication. The regulatory information focuses on the risk associated with high sodium intake and fluid retention.

Q: What are the long-term safety concerns associated with Metildopa?

Regulatory warnings related to prolonged use focus on potential hematologic effects and certain liver disorders, including hepatitis. Due to these potential effects, official guidelines indicate the importance of periodic monitoring of blood counts and liver function.

Q: What is the research evidence for Metildopa's use in non-pregnant adults?

According to official regulatory labeling, the primary approved indication for Methyldopa is the treatment of hypertension (high blood pressure). The medication is indicated broadly for the management of high blood pressure in adults, not restricted solely to pregnancy.

Q: Can Metildopa be taken with vitamins or mineral supplements?

Official interaction warnings state that taking Methyldopa with iron supplements (ferrous salts) can reduce how much Methyldopa the body absorbs. Regulatory information suggests that the administration of these two products should be separated by a period of time.

Q: Can I drive while taking Metildopa?

Official information advises that Methyldopa may cause side effects such as sedation or dizziness. Due to the potential for impaired alertness and coordination, official guidance recommends assessment of drug effects before engaging in activities like driving or operating machinery.

Q: Why might Metildopa be preferred over other blood pressure medicines?

Regulatory-supported guidance, such as the World Health Organization's list of essential medicines, cites Methyldopa as a recommended and effective treatment option for managing hypertension during pregnancy. This is the specific therapeutic setting where its use is most frequently highlighted.

Q: How is Metildopa eliminated from the body?

According to the official pharmacological description, Methyldopa is primarily cleared from the body through the urine. The regulatory description indicates that a high percentage of the absorbed dose is excreted in the urine as the unchanged drug and its main chemical breakdown product.

Q: Does Metildopa interact with common pain relievers like ibuprofen?

Official interaction lists note that Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a class that includes medicines like ibuprofen and aspirin, may lessen the intended blood pressure-lowering effects of Methyldopa.

Q: What should I know if I feel dizzy after starting Metildopa?

Dizziness or lightheadedness, particularly when rising from a lying or sitting position, is a listed common side effect of Methyldopa. This effect is identified in product information as orthostatic hypotension (a drop in blood pressure upon standing) and is documented as common.

Q: Is there a generic version of Metildopa available?

Official information confirms that Methyldopa is available as a generic formulation. It is the active ingredient in various products that have also been historically sold under brand names.

Q: Can Metildopa affect sleep patterns?

Regulatory documentation lists potential adverse effects on the nervous system and psychiatric disorders. These effects include general sedation and the occurrence of nightmares.

Q: Can Metildopa be taken on an empty stomach?

Regulatory guidance does not include any explicit instruction that Methyldopa must be taken with or without food. Regulatory information indicates that no food restrictions are mandated in the official label.

Q: Is Metildopa a first-line treatment for high blood pressure?

Regulatory-supported organizations like the WHO recommend it as a treatment option for hypertension in pregnancy. Treatment recommendations for other patient groups vary across clinical guidelines.

Q: Does Metildopa have any known interactions with herbal supplements?

Official regulatory advice recommends caution when taking Methyldopa with other products, including herbal supplements. Some specific interactions, such as with St. John's wort, are noted in supportive drug information.

Q: How long does the effect of one dose of Metildopa last?

The official product information states that the maximum blood pressure reduction occurs 4–6 hours after taking an oral dose. After the drug is stopped, blood pressure is documented to return to pretreatment levels usually within 24 to 48 hours.

Q: Is it true that Metildopa can cause a positive result on certain drug screens?

Regulatory labeling notes that Methyldopa can interfere with certain laboratory tests. Specifically, it can cause falsely high results when testing for urinary catecholamines due to a phenomenon called fluorescence.

Q: What should I know about stopping Metildopa?

Official product information states that if the medication is stopped, the blood pressure-lowering effect usually wears off, and hypertension is documented to return, typically within 48 hours.

Q: Does Metildopa interact with cold and flu medications?

Methyldopa should be used with caution when taken with certain other medicines, including those with adrenergic effects. This includes some ingredients often found in decongestants, as the combination may lead to a potential increase in blood pressure.

Q: Do studies support the long-term use of Metildopa?

The regulatory label includes specific warnings and monitoring recommendations related to side effects that may occur with prolonged Methyldopa therapy. The inclusion of this detailed guidance indicates the drug's intended use in chronic treatment scenarios.

Q: Can Metildopa cause skin rash or itching?

The official product information lists various dermatological reactions as possible adverse events. These include a general rash, urticaria (hives/itching), and other specific skin reactions.

Q: Is Metildopa a generic or brand-name drug?

Methyldopa is the generic, active ingredient. It is available today as a cost-effective generic formulation, and was also historically sold under various brand names.

Q: Does Metildopa affect sexual function?

Official regulatory documents list that Methyldopa may cause effects on the reproductive system. These effects can include decreased libido (interest in sex) and impotence (erectile dysfunction).

Q: Can people with a history of stroke use Metildopa?

The official regulatory label advises that the medication should be used with caution in patients who have symptoms of cerebrovascular insufficiency, which is reduced blood flow to the brain.

How should Metildopa be stored and disposed of?

How to Store and Dispose of Methyldopa

Methyldopa must be stored strictly according to regulatory labeling to maintain its stability.

Storage Requirements

Condition	Requirement
Temperature	Store tablets at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection	Keep in the original, tightly closed, light-resistant container. Protect from excess heat, moisture, and freezing.
Safety	Keep out of the reach and sight of children in a secure location.

Disposal Protocol

Unused or expired Methyldopa should be disposed of by following official guidelines. The preferred method is to utilize a medicine take-back program. If one is unavailable, dispose of the medication in the household trash by mixing it with an undesirable substance (e.g., used coffee grounds), sealing it, and discarding it. It is required to not flush this medication down the toilet or drain unless explicitly instructed to do so by a government source.

Metildopa